Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Pain
Interventions: Desmetramadol; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteer
Interventions: BIIB122, Rabeprazole; Drug
Lead sponsor: Biogen; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cancer
Interventions: Embodied Conversational Agent, REDCap Survey; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anthrax
Interventions: Active Anthrax Detect™ Plus (AAD Plus); Diagnostic Test
Lead sponsor: InBios International, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Tempe, Arizona • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Drug Interactions
Interventions: Telotristat etiprate, Midazolam; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Atorvastatin; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass (RYGB), Caloric Restriction, Exendin-9,39, Normal Saline; Procedure · Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 20 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Trichomonas Vaginalis
Interventions: Point of care tests; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Transtibial Amputation, Peripheral Artery Disease, Diabetes Mellitus
Interventions: Error-augmentation gait training, Error-correction gait training, Supervised walking; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Richmond, Virginia

Conditions: Hypertension
Interventions: losartan potassium / hydrochlorothiazide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Chronic Pain
Interventions: Oxymorphone ER; Drug
Lead sponsor: MedVadis Research Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Wellesley Hills, Massachusetts

Conditions: COVID-19, COVID-19 Pandemic
Interventions: COVID-19 walk-up, on-site testing strategy, Community Health Worker (CHW) leading testing navigation and general preventive care reminders, No-cost self-testing kit vending machines; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed
Enrollment: 6,527 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Ysidro, California

Conditions: Congenital Hyperinsulinism
Interventions: Exendin-(9-39), placebo; Drug
Lead sponsor: Diva De Leon; Other
Eligibility: 6 Months to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ewing Sarcoma
Interventions: LX-101; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 10 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: certolizumab pegol; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Aventura, Florida • Oklahoma City, Oklahoma

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Metabolic Syndrome
Interventions: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count; Behavioral
Lead sponsor: Family Medicine Residency of Idaho; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Caldwell, Idaho • Jerome, Idaho • Nampa, Idaho

Conditions: Epilepsy
Interventions: ketogenic diet; Other
Lead sponsor: Mid-Atlantic Epilepsy and Sleep Center, LLC; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteer
Interventions: ASTX660; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rare CNS Tumor, FOXR2-activated, BCOR ITD Sarcoma, CNS Sarcoma, PLAG-altered Tumors, Mesenchymal Tumor
Interventions: Personalized Treatment Recommendation; Other
Lead sponsor: Adriana Fonseca; Other
Eligibility: Up to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Suicidal Ideation, Depression, Alcohol Abuse
Interventions: Intranasal ketamine, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumor Induced Osteomalacia (TIO), Epidermal Nevus Syndrome (ENS)
Interventions: Burosumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 7
States / cities: Golden, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 4 more

Conditions: Tumors
Interventions: Lenvatinib, Midazolam; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Detroit, Michigan • The Bronx, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25, Glucose-dependent Insulinotropic Polypeptide plus Xenin-25; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Improving PRO for Patients With Cancer Using ECAs and Data Visualization

Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.

The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes

Accuracy and Acceptability of Self-Diagnostic Methods for Vaginitis in Adolescent Females

Optimizing Gait Rehabilitation for Veterans With Non-traumatic Lower Limb Amputation

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

Effect of Extended-release Oxymorphone Taken With or Without Food on Cognitive Functioning

Community-engaged Optimization of COVID-19 Rapid Evaluation And TEsting Experiences

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

Blood Markers of Early Pancreas Cancer

Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial

Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy

Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers

Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function